Proton Boost in Prostate Cancer
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/22/2018 |
| Start Date: | April 16, 2018 |
| End Date: | April 2033 |
Assessing the Effectiveness of Photon Therapy With a Proton Therapy Boost in the Treatment of Prostate Cancer as Compared to Photon Therapy Alone
This study uses photon radiation with a proton boost to treat prostate cancer. The purpose of
this study is to determine if proton therapy as a boost following photon intensity modulated
radiation therapy (IMRT) produces decreased toxicity as compared to conventional photon IMRT
alone in the treatment of prostate cancer. Our secondary objective is to determine the
effectiveness of this treatment regimen. Effectiveness will be determined by length of time
to progression or recurrence of disease and overall survival. Patients on this study will be
treated with a course of photon radiation therapy followed by a boost course of proton
radiation.
this study is to determine if proton therapy as a boost following photon intensity modulated
radiation therapy (IMRT) produces decreased toxicity as compared to conventional photon IMRT
alone in the treatment of prostate cancer. Our secondary objective is to determine the
effectiveness of this treatment regimen. Effectiveness will be determined by length of time
to progression or recurrence of disease and overall survival. Patients on this study will be
treated with a course of photon radiation therapy followed by a boost course of proton
radiation.
Inclusion Criteria:
- ≥18 years of age
- Diagnosis of low risk prostate cancer (T1c-T2a, Gleason 6, Prostate Specific Antigen
(PSA) <10) -OR-
- Diagnosis of intermediate risk prostate cancer (T1c-T2c, Gleason 7 and/or PSA 10- 20)
- Life expectancy >10 yrs
- Physically and mentally capable of signing the consent form of their own volition
Exclusion Criteria:
- < 18 years of age
- Diagnosis of high risk prostate cancer (T3 or higher, Gleason >7 and/or PSA >20)
- Current or historical use of androgen deprivation therapy
- Nodal positivity
- Previous cancer excluding non-melanoma skin cancer
- History of prostatectomy
- History of brachytherapy for prostate cancer
- Life expectancy <10 yrs
- Physically or mentally incapable of signing the consent form of their own volition
We found this trial at
1
site
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
